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Abstract
: The MASS III Trial is a large project from a single institution, The Heart Institute of the University
of Sao Paulo, Brazil (InCor), enrolling patients with coronary artery disease and preserved
ventricular function. The aim of the MASS III Trial is to compare medical effectiveness, cerebral
injury, quality of life, and the cost-effectiveness of coronary surgery with and without of
cardiopulmonary bypass in patients with multivessel coronary disease referred for both strategies.
The primary endpoint should be a composite of cardiovascular mortality, cerebrovascular accident,
nonfatal myocardial infarction, and refractory angina requiring revascularization. The secondary
end points in this trial include noncardiac mortality, presence and severity of angina, quality of life
based on the SF-36 Questionnaire, and cost-effectiveness at discharge and at 5-year follow-up. In
this scenario, we will analyze the cost of the initial procedure, hospital length of stay, resource
utilization, repeat hospitalization, and repeat revascularization events during the follow-up.
Exercise capacity will be assessed at 6-months, 12-months, and the end of follow-up. A
neurocognitive evaluation will be assessed in a subset of subjects using the Brain Resource Center
computerized neurocognitive battery. Furthermore, magnetic resonance imaging will be made to
detect any cerebral injury before and after procedures in patients who undergo coronary artery
surgery with and without cardiopulmonary bypass.
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Introduction
Coronary bypass surgery performed without the use of
cardiopulmonary bypass (off-pump surgery) has been
used sporadically since the beginning of the bypass sur-
gery era in 1967, but the use of this strategy increased sub-
stantially during the 1990s. The major reason for the
increased use of off-pump surgery was the hope that this
strategy would decrease perioperative morbidity and pos-
sibly mortality by eliminating cardiopulmonary bypass
(on-pump surgery). The fear concerning off-pump surgery
has been that the difficulty of operating with the heart
beating would lead to less-complete and less-effective
revascularization at the time of surgery and worse long-
term outcomes. These advantages and disadvantages have
been examined in several studies that compared the out-
comes of patients undergoing off-pump and on-pump
surgery [1-4]. Observational trials often have shown big-
ger differences in short-term complications, usually in
favor of off-pump surgery, but analyses of these trials are
complicated by patient selection. On the other hand, ran-
domized trials usually have shown small differences in
perioperative outcomes, usually slightly in favor of off-
pump surgery, mostly including low-risk patients.
Long-term follow-up studies, both randomized and
observational, have sometimes noted inferior outcomes
after off-pump compared with on-pump surgery, mani-
fested as decreased patency, increased risk of repeat revas-
cularization, or increased mortality. Yet, other studies
have shown no or few long-term differences that usually
have been attributed to a lack of experience with off-pump
surgery [3,4].
The absence of guidelines for the use of one or the other
technique has allowed individual decision-making
according to the experience of the surgeon [5]. The ration-
ality for off-pump surgery is reduced morbidity, and
reduced adverse effects attributed to on-pump surgery,
including an inflammatory response caused by the circu-
lation of blood through the cardiopulmonary circuit and
the formation of microemboli [6]. In this context, the
advantages and disadvantages of both strategies have been
considered, and critical appraisal is made of the evidence
available. The validity of evidence has been assessed using
different criteria, including study design, size of surgical
populations, and the quality of statistical analyses [7].
Objectives
The aim of the MASS III Trial is to compare medical effec-
tiveness, safety, cerebral injury, quality of life, cost-effec-
tiveness of coronary surgery with and without of
cardiopulmonary bypass in on-pump and off-pump tech-
niques in patients referred for both strategies. The primary
endpoint should be a composite of cardiovascular mortal-
ity, cerebrovascular accident, nonfatal myocardial infarc-
tion, and refractory angina requiring revascularization.
Rationale
Coronary artery surgery with and without cardiopulmo-
nary bypass plays an important role in the treatment and
management of ischemic heart disease. Both treatment
strategies have their own advantages and disadvantages.
On-pump strategies provide more complete revasculariza-
tion and require fewer repeat interventions compared
with off-pump surgery. However, the procedure is more
invasive and is associated with cardiac as well as noncar-
diac surgery morbidity [8,9]. Major neurological compli-
cations after conventional cardiac surgery have been
reported to occur in 3.1% of patients [10]. Additionally,
neuropsychological dysfunction is increasingly being rec-
ognized as a complication of on-pump surgery. Cognitive
deficits can be documented accurately [11] and may occur
in up to 38% of patients [12]. The increasing awareness of
the cerebral complications following on-pump surgery
especially in the elderly [13] has led to a renewed interest
in coronary surgery on the beating heart. The Utrecht
Octopus method is a technique developed to avoid cardi-
opulmonary bypass and the complications associated
with its use [14].
The role of off-pump surgery, however, is the subject of
debate. Opponents emphasize the excellent results of con-
ventional on-pump surgery and express their concerns
about the safety, early anastomotic failure, and eventual
incomplete revascularization related to off-pump strate-
gies [15].
Moreover, although widely accepted, the suspected delete-
rious role of cardiopulmonary circulation in the genesis of
adverse cerebral outcomes has not been completely
proved, simply because an appropriate control group has
never been available. A limited number of randomized
clinical trials have directly compared coronary surgery
with and without cardiopulmonary bypass circulation
[16,17].
Methods
The MASS III trial is a single-center, prospective, rand-
omized clinical trial, of which the design, timing of inves-
tigation and definitions of main outcome events are
presented in Figure 1, Table 1 and Table 2, respectively.
The MASS III Trial provided external blinded committee.
So, all nonfatal clinical events, including MI, Stroke,
refractory angina requiring revascularization, will
undergo central adjudication by independent Clinical
Events Committee (CEC). The role of CEC will be to
insure that all primary endpoint are adjudicated uni-
formly. Furthermore a cardiopulmonary surgeon, a cardi-
ologist and a neurologist formed the clinical eventTrials 2008, 9:52 http://www.trialsjournal.com/content/9/1/52
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committee and confirm and classify the major adverse car-
diac and cerebrovascular events (MACCE), blinded to the
treatment. To verify whether important differences in the
incidence of MACCE exist between the treatment groups,
the Data Monitoring Committee performed an interim
analysis after the first patients 100 had entered each arm
of study. The three members of this committee are experi-
enced in patient-oriented research, are independent of the
study, and may also offer unsolicited recommendations.
The sample size calculations are based on the assump-
tions that the actuarial freedom from cardiac event rate 5
years after on-pump surgery is 95% and that off-pump
surgery did not decrease the rate by more than 10%. The
α error is set at 0.05, and the β error is set at 0.20. The
required sample size is 153 in each group for a total of 306
patients.
Primary Composite End Points
The primary endpoint should be a composite of cardio-
vascular mortality, cerebrovascular accident, nonfatal
myocardial infarction, and refractory angina requiring
revascularization across 5 years of follow-up.
It is expected that the need for repeat revascularization
after coronary surgery with or without cardiopulmonary
bypass will be similar. As mentioned, a controversy dis-
cussed in the literature indicates that coronary surgery
with or without cardiopulmonary bypass circulation has
equal effectiveness in terms of myocardial revasculariza-
tion. Therefore, repeat interventions can be a major clini-
cal event. Therefore repeat interventions will be
considered as early failure of treatment in this study. In
addition, the use of cardiopulmonary bypass can be asso-
ciated with considerable cerebral injury, in particular neu-
ropsychological deficits [11,12]. So, the primary end
point in the comparison of surgery with and without car-
diopulmonary bypass is also a cerebral event. This is
defined as the proportion of patients free of the combined
event of fatal and nonfatal cardiovascular accidents and
cognitive dysfunction, whichever occurs first, to be deter-
mined in-hospital and during the 5 years of follow-up.
Secondary End Points
The secondary end points in this trial include non-cardiac
mortality, presence and severity of angina, quality of life
using the SF-36 Questionnaire [18], and cost-effectiveness
at discharge and at 5-year follow-up. In this scenario, we
will analyze the cost of the initial procedure, hospital
length of stay, resource utilization, repeat hospitalization,
and repeat revascularization events during the follow-up.
Exercise capacity will be assessed at 6-month, 12-month,
and end follow-up.
In the MASS III trial, no difference is expected in cardiac
outcome; nevertheless, cardiac death, myocardial infarc-
tion, and repeat revascularization procedures will be
assessed in-hospital and at 1, 6, and 12 months and yearly
thereafter. Cognitive function will also be assessed at
baseline and at 1, 6, and 12 months. It is expected that
most patients will show a decline in this early postopera-
tive period. However, the rapid recovery and short hospi-
tal stay of the nonselected patients who undergo coronary
surgery in our hospital without extracorporeal circulation
suggest that the benefits of this strategy may be especially
reflected in a reduction of neuropsychological injury in
the early postoperative period.
Patients
Patients with angiographically documented proximal
multivessel coronary stenosis of more than 70% by visual
assessment, stable angina, and preserved ventricular func-
tion were considered for inclusion in this study. Further-
more, they were eligible if they were referred for isolated
coronary bypass surgery for the first time and the off-
pump procedure was deemed technically feasible.
Patients were enrolled and randomized if surgeons agreed
that revascularization could be attained by either strategy.
This selection predominantly depends on the precise loca-
tion of the stenoses, the anticipated capacity of the heart
to endure temporary occlusion of the involved coronary
arteries, and hemodynamic consequences of local immo-
bilization of the ventricular wall. In these conditions,
bypass grafting of posterior coronary arteries may result in
a significant drop in left ventricular stroke volume upon
presentation of these vessels [19].
All angiograms were reviewed and a surgical plan was doc-
umented before randomization. The selection criteria for
the MASS III trial are depicted in Table 3.
Algorithm MASS III trial
Figure 1
Algorithm MASS IIItrial. Only patients eligible for off-
pump can enter the study. *Crossing-over in presence of 
electric or hemodynamic instability.
*Crossing-over in presence of electric or hemodynamic instability
Figure 1 Algorithm MASS III trial. Only patients eligible for off-pump can enter the study.
Patients requiring revascularization
Eligible for both, on-pump and off-pump surgery
Off-pump surgery
On-pump surgery *
On-pump surgeryTrials 2008, 9:52 http://www.trialsjournal.com/content/9/1/52
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Surgical Technique
General
Trial operators were required to perform optimum coro-
nary revascularization in accordance with current best
practices. The surgery was performed by physicians expe-
rienced in both on-pump and off-pump bypass surgery.
Surgical access to the heart was through a standard
median sternotomy in all cases. All incisions and closure
techniques were the same for groups, limiting variability
and maintaining blinding of group assignment for
patients, family, and referring cardiologists. A cell saver
reservoir (COBE Cardiovascular, Inc. Arvada, CO) was
spun down and returned to all patients when the quantity
was sufficient.
Off-pump strategies
Off-pump surgery used the Octopus stabilizer described
in detail elsewhere [14]. In brief, the distal ends of the 2
suction arms of the stabilizer are placed on the beating
heart on both sides of the target coronary artery. The prox-
imal parts are fixed to the operating table. Through the
application of negative pressure, the target area of the
heart is sufficiently immobilized to allow the safe con-
struction of the anastomosis of the graft with the recipient
artery.
On-pump technique
Conventional coronary artery surgery with cardiopulmo-
nary bypass was accomplished with every effort made to
minimize the impact of cardiopulmonary bypass. Patients
without diabetes received 1 gram of hydrocortisone
sodium succinate (SoluCortef, Pharmacia & Upjohn Co.,
New York, NY) intravenously before of anesthesia. This
procedure will be made only in the on-pump technique.
The patients were routinely cooled to 34° for operations
with 3 grafts and 32° for 4 grafts or more. Cold-blood car-
Table 1: Schedule of Measurements
S P D 1 m 3 m 6 m 12 m 24 m 36 m 48 m 60 m
Angiograms X X X
History/events X X X X X X X X X X X
Anginal assessment X X X X X X X X X X X
Medications X X X X X X X X X X X
Physical examination X X X X X X X X X X X
E l e c t r o c a r d i o g r a p h y X X X X X X XXXXX
Echocardiography X X
Magnetic Resonance Imaging X X
Neuropsychological tests X X X X
R o u t i n e  l a b o r a t o r y X X X X X X XXXXX
ECG stress tests X X X
Resource utilization X X X X X X X X X X
Quality of life X X X X X X X
Cost-effectiveness X X
Working status X X
Abbreviations: S = preprocedural screening; P = procedure; D = discharge; 1 m = 1 month after intervention; 3 m to 60 m denotes months after 
intervention.
Table 2: Definitions of Main Composite Primary End Points
Cardiovascular death Cardiovascular mortality is included in the composite primary end point. Cardiovascular death includes fatal 
myocardial infarction, sudden death, untreated heart failure, fatal cerebral infarction, and hemorrhage and 
procedure-related fatal bleeding.
Cerebrovascular accident Patients with a focal neurological deficit of central origin lasting more than 72 hours, or a focal neurological deficit 
of central origin lasting more than 24 hours with imaging evidence of cerebral infarction or intracerebral 
hemorrhage, or a nonfocal encephalopathy lasting more than 24 hours with imaging evidence of cerebral 
infarction or hemorrhage adequate to account for the clinical state. Retinal arterial ischemia or hemorrhage is also 
included. To fulfill the definitions of stroke, the deficit must be new, sudden in conset, and not attributable to any 
more likely alternative cause.
Myocardial infarction Elevation of specific cardiac enzymes within 14 days of a revascularization procedure and presence of new Q 
waves in at least 2 or more contiguous leads and CK-MB elevation 5 × normal (see Appendix).
Further revascularization The initial revascularization is considered completed when the patient is transferred from the operating room to 
bed. Refractory angina requiring revascularization was considered an end point.Trials 2008, 9:52 http://www.trialsjournal.com/content/9/1/52
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dioplegia was accomplished with anterograde delivery
through the aortic root and retrograde delivery through
the coronary sinus. A heparinization protocol of 300 U
per kilogram for on-pump surgery and half-dose heparin
for off-pump surgery was followed. Protamine was used
to reverse the effects of heparinization only in the on-
pump patients. All anastomoses were sutured by hand. In
the off-pump patients, intracoronary shunts were not
used routinely; indications for use included poor visibil-
ity, ST-segment changes, and homodynamic instability.
Quality of Life and Cost-effectiveness
Health-related quality of life and treatment costs will be
assessed to evaluate the relative cost-effectiveness for the
MASS III trial population. Heath-related quality of life
and functional status will be assessed using a combina-
tion of generic and disease-specific measures selected to
cover a broad range of potential health domains that may
be affected by coronary artery disease, its treatments, and
complications. The SF-36 Questionnaire will be used to
assess patients' utilities [18]. Utilities are a global rating of
health that reflects a patient's preference for his current
health status relative to perfect health and are particularly
important outcome measures for cost-effectiveness analy-
sis [20]. Medical care resource utilization and cost data
will be collected prospectively for the index hospitaliza-
tion up to discharge and 5-year follow-up for all patients
including all costs associated with the index procedure.
For each index revascularization procedure, detailed
resource utilization will be collected using a standardized
case report form. Follow-up medical resource utilization
(including hospitalization, out-patient services, and cardi-
ovascular medications) will be assessed by detailed ques-
tionnaires that will be completed during each scheduled
patient contact.
Neurocognitive Evaluation
In evaluation of CABG patients with multivessel disease,
neurocognitive status is a crucial outcome variable, along
with major adverse cardiac and cerebrovascular event. A
subset of subjects will be assessed using the Brain
Resource Center [21] computerized neurocognitive bat-
tery. The battery is relatively short and easy to administer
and score. The computerized battery measures 5 basic
functions: memory, mental and psychomotor speed
attention, verbal fluency, and cognitive flexibility.
Statistical Analysis Plan
Patients eligible for the MASS III trial are invited to the
outpatient clinic to receive additional information. Can-
didates for the trial admitted to a referral hospital are vis-
ited by one of the trial monitors. After giving consent,
patients are randomized. To ensure a reasonable balance,
assignment is performed according to a computer-gener-
ated list of random permuted blocks that are unknown by
Table 3: Eligibly criteria.
INCLUSION CRITERIA
Male or female age 18 years or older.
Patients with stable angina pectoris and/or documented ischemia due to multivessel disease and preserved ventricular function.
Angiographically confirmed multivessel CAD lesions with ≥70% in at least 2 major epicardial vessels and at least 2 separate coronary artery 
territories: LAD, LCX, and RCA.
Patients who are eligible for coronary surgery both with and without cardiopulmonary bypass circuit.
Nonsignificant left main stenoses can be included.
Willing to comply with all follow-up study visits.
Signed and received a copy of the informed consent.
EXCLUSION CRITERIA
Age under 18 years
Severe congestive hearth failure NYHA Class III or IV or pulmonary edema.
Prior valve replacement or CABG coronary surgery.
Prior PCI with stent implantation within 6 months.
Prior stroke within 6 months or patients with stroke at more than 6 months with significant residual neurological involvement, as reflected in a 
Rankin score > 1.
Need for concomitant major surgery, eg, valve replacement, resection ventricular aneurysm, congenital heart disease vascular surgery of the 
carotid artery, or thoracic-abdominal aorta.
Concomitant medical disorders making clinical follow-up at least 5 years unlikely or impossible, eg, neoplasic, hepatic, or other severe disease.
Q-wave myocardial infarction in the previous 6 weeks.
Hemorrhagic diathesis or hypercoagulability.
Thoracic deformations technically precluding surgery without extracorporeal circulation.
Unable to give informed consent.Trials 2008, 9:52 http://www.trialsjournal.com/content/9/1/52
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the investigators. After randomization, patients are sched-
uled for the allotted treatment.
The goal of the main analysis is to compare the primary
outcome events in this trial. Kaplan Meyer curves will be
used for graphic comparison. All values are expressed as
mean ± standard deviation or percentage. The continuous
variables are compared by the Wilcox rank sum test,
whereas the discrete variables are analyzed with Fisher's
exact test. The occurrence of outcome events will be com-
pared by means of Cox's proportional hazards model
yielding a hazard ratio. The primary data analysis will be
based on the intention-to-treat principle. Interim analyses
will be carried out annually to evaluate the safety.
For both treatment strategies, the cost of diagnostic proce-
dures, treatment procedures, complications, and short-
and long-term differences in effects will be estimated.
Marginal costs in monetary terms will be calculated by
multiplying unit costs and marginal medical consump-
tion as recorded for each patient.
Discussion
The MASS III Trial is designed to include patients who
need coronary revascularization for relieving angina and
better exercise tolerance. Off-pump surgery is a well-estab-
lished alternative to on-pump surgery in terms of short
and mid-term outcomes. However, the benefit of off-
pump surgery may depend on the clinical status of
patients and the majority of studies were carried out on
low-risk surgical patients. Recently, patients with higher
risk profile are increasing and in the context of elderly
patients with comorbidities, the off-pump surgery might
have an important role.
The lack of statement guidelines regarding this issue
leaves the decision of using extracorporeal circulation to
individual surgeons, and many of them remain unwilling
to adopt off-pump surgery technique. This hesitation is
still justified, since a more demanding technically proce-
dure is being suggested instead of a successful, well-stud-
ied, and reproducible approach. Yet, if the benefits of off-
pump surgery became conclusive, this would have several
implications for the future of cardiac surgery regarding to
quality of patient care as well as cost-effectiveness of the
procedure. The MASS III trial is a great opportunity to
address all these issues, and it will add relevant informa-
tion in this field.
Ethical Considerations
MASS III is conducted in accordance with the principles of
the Declaration of Helsinki and with laws and regulations
of our country. The Ethics Committee of the Heart Insti-
tute of University of Sao Paulo, Brazil approved the study
protocol. The attending physician obtained written
informed consent from the study participants. The patient
is told that he or she will be randomized to surgery with
or without extracorporeal circulation.
Final Considerations
MASS III is designed to include patients who need coro-
nary artery surgery and for whom 2 surgical strategies are
feasible. The results of the study may facilitate selection of
the most appropriate strategy for individual patients and
foster the appropriate use of available resources.
Competing interests
None of the authors of the MASS III Trial has a financial
or any other relation that would pose a conflict of interest.
Authors' contributions
Each of the authors had substantial contributions either
on conception and design or on the drafting of the article
and critical revision for this important intellectual con-
tent. Specifically, WH is the Principal Investigator for the
study described in the manuscript, WH, NHML, BJG, SAO
and JAFR participated actively in designing and perform-
ing the research. Additionally, SAO, LAD, ACH, and NAS
performed all the surgeries procedures. WH and NHML
are following all the patients during the follow-up clinical
visits. Finally, CCC, FSP, and NHML planed the Ancillar-
ies Studies. All authors participated in drafting and revis-
ing the manuscript and all authors read and approved the
final manuscript.
Appendix: Definition of myocardial infarction
A – Q-Wave infarction
See ECG-criteria new Q-wave infarction
Enzyme elevation as follows:
CK-MB elevation 5 × upper limit of normal
B – Enzymatic/non-Q-wave infarction
Enzyme elevation as follows:
CK-MB elevation 5 × upper limit of normal
C – ECG Criteria New Q-Wave myocardial infarction
New QS in 2 associated leads in the absence of left
bundle-branch block (LBBB)/Wolf-Parkinson White
Syndrome.
New QS in 2 associated leads, defined as ≥ 0.04 sec-
onds broad and/or Q/R ratio ≥ 1/4Trials 2008, 9:52 http://www.trialsjournal.com/content/9/1/52
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Posterior wall infarction: new Broad R-wave (≥ 0.04
seconds) and tall R/wave (R/S ratioЈ1 or R-wave ≥ 0.5
mv) in lead V1 and V2 in the absence of right bundle-
branch block (RBBB)/right ventricular hypertrophy
(RVH)
New permanent LBBB and enzyme elevation
Reversed R-wave progression precordial: decrement R-
wave ≥ 0.2 mv in 2 consecutive precordial leads and
enzyme elevation.
Any new Q-wave in lead V2 and V3 and enzyme eleva-
tion.
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